New HIV drug combo shows similar virus control to standard care in people with resistance markers

People with HIV often face tough choices when their bodies show signs of resistance to common medicines. This study looked at a specific drug mix called dolutegravir plus lamivudine compared to a standard mix involving tenofovir or emtricitabine. The researchers focused on a group of 211 people who had never taken antiretroviral drugs before. These participants had specific genetic markers known as tRAMs that can signal resistance to older treatments. The main question was whether the new mix could still work effectively for them. After 48 weeks, the results showed that 85.7 percent of people on the new mix had their virus levels drop below the detection limit. In the standard mix group, 91.7 percent achieved the same goal. The difference between these numbers was not statistically significant, meaning the new mix performed just as well as the standard one for this specific group. The study did not report any safety issues or reasons for people to stop taking their medication during the trial. However, the researchers noted that they did not know the full resistance status of the participants until the study ended. This lack of information limits how broadly these results can be applied right now. The findings suggest that this specific drug combination is a viable option for people with these resistance markers, but more data is needed to confirm this for everyone.